Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 10/20 | 0.59 |
| ▸ | JAK2 | O60674 | 8/20 | 0.59 |
| ▸ | JAK3 | P52333 | 7/20 | 0.59 |
| ▸ | AURKA | O14965 | 6/20 | 0.59 |
| ▸ | IGF1R | P08069 | 3/20 | 0.59 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.59 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.59 |
| ▸ | RET | P07949 | 2/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.59 |
| ▸ | FLT3 | P36888 | 2/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.59 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | FYN | P06241 | 1/20 | 0.59 |
| ▸ | FLT1 | P17948 | 1/20 | 0.59 |
| ▸ | LTK | P29376 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.59 |
| ▸ | CLK2 | P49760 | 1/20 | 0.59 |
| ▸ | CDK7 | P50613 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL588730 | 0.91 | NTRK1 (0.73) | NTRK1JAK2JAK3AURKAIGF1R | |
| SCHEMBL18281508 | 0.91 | NTRK1 (0.73) | NTRK1JAK2JAK3AURKAIGF1R | |
| SCHEMBL31060183 | 0.91 | NTRK1 (0.73) | NTRK1JAK2JAK3AURKAIGF1R | |
| SCHEMBL29434985 | 0.91 | NTRK1 (0.73) | NTRK1JAK2JAK3AURKAIGF1R | |
| Phosphoric Acid SCHEMBL3041888 | 0.86 | NTRK1 (0.66) | NTRK1JAK2JAK3AURKAIGF1R | |
| Maleic Acid SCHEMBL4904780 | 0.84 | NTRK1 (0.63) | NTRK1JAK2JAK3AURKAIGF1R | |
| SCHEMBL23808896 | 0.83 | NTRK1 (0.75) | NTRK1JAK2JAK3AURKAIGF1R | |
| SCHEMBL3034183 | 0.82 | NTRK1 (0.71) | NTRK1JAK2JAK3AURKAIGF1R | |
| SCHEMBL3349894 | 0.82 | JAK2 (0.75) | NTRK1JAK2JAK3AURKAIGF1R | |
| SCHEMBL3345053 | 0.82 | JAK2 (0.75) | NTRK1JAK2JAK3AURKAIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771698-B2 | Methods of treating cholangiocarcinoma | FOUNDATION MEDICINE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | NTRK1 1066/4885JAK2 2701/4885JAK3 3043/4885 |
| US-11771698-B2 | Methods of treating cholangiocarcinoma | HCCS, PNLIP, LIPA | NTRK1 2894/4885JAK2 1308/4885JAK3 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.